‡a
Author's Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain
‡a
palivizumabinthepreventionofsevererespiratorysyncytialvirusinfectioninchildrenwithcongenitalheartdiseaseanovelcostutilitymodelingstudyreflectingevidencebasedclinicalpathwaysinspain
‡A
Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain
‡9
1